Cardiff Oncology (CRDF) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| William Blair | Downgraded | Outperform → Market Perform | — | Aug 12, 2026 |
| Craig-Hallum | Downgraded | Buy → Hold | $2.00 from $10.00 | Jun 3, 2026 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | Jun 1, 2026 |
| TD Cowen | Downgraded | Buy → Hold | — | Jun 1, 2026 |
| Piper Sandler | Maintained | Overweight | $6.00 from $10.00 | Feb 25, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Jan 28, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 from $18.00 | Aug 6, 2025 |
| Ladenburg Thalmann | Initiated Coverage | Buy | $19.00 | Jul 8, 2025 |
| Jefferies | Initiated Coverage | Hold | $3.50 | Jun 24, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $18.00 from $17.00 | May 9, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $17.00 from $13.00 | Feb 28, 2025 |
| Piper Sandler | Maintained | Overweight | $10.00 from $7.00 | Dec 13, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 from $14.00 | Nov 8, 2024 |
| Craig-Hallum | Initiated Coverage | Buy | $8.00 | Sep 6, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 | May 6, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 from $12.00 | Mar 6, 2024 |
| Piper Sandler | Maintained | Overweight | $7.00 from $5.00 | Mar 1, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $12.00 from $13.00 | Aug 11, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $13.00 from $14.00 | Aug 8, 2023 |
| HC Wainwright & Co. | Maintained | Buy | $14.00 from $15.00 | May 9, 2023 |
Frequently asked questions
Is CRDF a buy, sell, or hold?
Analysts covering Cardiff Oncology currently average a Hold rating: 1 buy, 5 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on CRDF?
On Aug 12, 2026, William Blair downgraded Cardiff Oncology to Market Perform.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.